Kumar Neil sold 8,721 shares of BridgeBio Pharma, Inc. at $69.01 for −$602k on Sep 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Executive Officer
Chief Executive Officer
Filed Sep 21, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$601,867.61Shares × reported price
Shares traded
8,721Common Stock
Price per share
$69.01Reported price. Read footnotes for ranges.
% of reported position traded
1.72%This security and ownership context
Holdings after
496,965Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Trade date
Sep 17, 2026Sell
Filed
Sep 21, 2026, 6:21 PM ET4-day reporting delay
Accession
0001470831-26-000897Code S · Transaction 227066
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 505,686 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 17, 2026Sell1,279$69.57−$88,979.52Trade 227067
2 transaction rows in this filing. Joint filers share the same rows.

BBIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BBIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +25%1w ago +8.8%1d ago +2.5%
Returns since7d −1.6%30d +1.7%90d180d1y

Footnotes in full

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F2: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. F4: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.